Literature DB >> 21119025

A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.

Margaret A Park1, Hossein A Hamed, Clint Mitchell, Nichola Cruickshanks, Rupesh Dash, Jeremy Allegood, Igor P Dmitriev, Gary Tye, Besim Ogretmen, Sarah Spiegel, Adly Yacoub, Steven Grant, David T Curiel, Paul B Fisher, Paul Dent.   

Abstract

Agents that generate reactive oxygen species (ROS) are recognized to enhance MDA-7/IL-24 lethality. The present studies focused on clarifying how such agents enhanced MDA-7/IL-24 toxicity in renal cell carcinoma cells (RCCs). Infection of RCCs with a tropism-modified serotype 5/3 adenovirus expressing MDA-7/IL-24 (Ad.5/3-mda-7) caused plasma membrane clustering of CD95 and CD95 association with pro-caspase 8, effects that were enhanced by combined exposure to 17-N-allylamino-17-demethoxygeldanamycin (17AAG), As(2)O(3), or fenretinide and that correlated with enhanced cell killing. Knockdown of CD95 or expression of cellular FADD (Fas-associated protein with death domain)-like interleukin-1β-converting enzyme inhibitory protein, short form (c-FLIP-s) blocked enhanced killing. Inhibition of ROS generation, elevated cytosolic Ca(2+), or de novo ceramide synthesis blocked Ad.5/3-mda-7 ± agent-induced CD95 activation and the enhancement of apoptosis. Ad.5/3-mda-7 increased ceramide levels in a PERK-dependent fashion that were responsible for elevated cytosolic Ca(2+) levels that promoted ROS generation; 17AAG did not further enhance cytokine-induced ceramide generation. In vivo, infection of RCC tumors with Ad.5/3-mda-7 suppressed the growth of infected tumors that was enhanced by exposure to 17AAG. Our data indicate that in RCCs, Ad.5/3-mda-7-induced ceramide generation plays a central role in tumor cell killing and inhibition of multiple signaling pathways may have utility in promoting MDA-7/IL-24 lethality in renal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119025      PMCID: PMC3061366          DOI: 10.1124/mol.110.069484

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  48 in total

1.  Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

Authors:  Hossein A Hamed; Adly Yacoub; Margaret A Park; Patrick J Eulitt; Rupesh Dash; Devanand Sarkar; Igor P Dmitriev; Maciej S Lesniak; Khalid Shah; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Authors:  Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein.

Authors:  Moira Sauane; Rahul V Gopalkrishnan; Heng-Tong Choo; Pankaj Gupta; Irina V Lebedeva; Adly Yacoub; Paul Dent; Paul B Fisher
Journal:  Oncogene       Date:  2004-10-07       Impact factor: 9.867

Review 4.  Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment.

Authors:  Meghan B Azad; Yongqiang Chen; Spencer B Gibson
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

5.  Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.

Authors:  Adelaide Greco; Altomare Di Benedetto; Candace M Howard; Sarah Kelly; Rounak Nande; Yulia Dementieva; Michele Miranda; Arturo Brunetti; Marco Salvatore; Luigi Claudio; Devanand Sarkar; Paul Dent; David T Curiel; Paul B Fisher; Pier P Claudio
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

6.  Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis.

Authors:  Moira Sauane; Zao-Zhong Su; Rupesh Dash; Xiang Liu; James S Norris; Devanand Sarkar; Seok-Geun Lee; Jeremy C Allegood; Paul Dent; Sarah Spiegel; Paul B Fisher
Journal:  J Cell Physiol       Date:  2010-03       Impact factor: 6.384

Review 7.  Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24.

Authors:  Luni Emdad; Irina V Lebedeva; Zhao-zhong Su; Pankaj Gupta; Moira Sauane; Rupesh Dash; Steven Grant; Paul Dent; David T Curiel; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Biol Ther       Date:  2009-03-08       Impact factor: 4.742

8.  A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Authors:  Sandra Turcotte; Denise A Chan; Patrick D Sutphin; Michael P Hay; William A Denny; Amato J Giaccia
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

9.  Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.

Authors:  Nitai C Hait; Jeremy Allegood; Michael Maceyka; Graham M Strub; Kuzhuvelil B Harikumar; Sandeep K Singh; Cheng Luo; Ronen Marmorstein; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel
Journal:  Science       Date:  2009-09-04       Impact factor: 47.728

10.  PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells.

Authors:  Adly Yacoub; Hossein A Hamed; Jeremy Allegood; Clint Mitchell; Sarah Spiegel; Maciej S Lesniak; Besim Ogretmen; Rupesh Dash; Devanand Sarkar; William C Broaddus; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

View more
  14 in total

1.  Characterization of the canine mda-7 gene, transcripts and expression patterns.

Authors:  Maninder Sandey; R Curtis Bird; Swadesh K Das; Devanand Sarkar; David T Curiel; Paul B Fisher; Bruce F Smith
Journal:  Gene       Date:  2014-05-24       Impact factor: 3.688

Review 2.  The development of MDA-7/IL-24 as a cancer therapeutic.

Authors:  Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Xiang-Yang Wang; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zhao-zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej S Lesniak; Steven Grant; David T Curiel; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2010-08-21       Impact factor: 12.310

Review 3.  MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.

Authors:  Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zhao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej Lesniak; Steven Grant; David T Curiel; Paul B Fisher
Journal:  Anticancer Drugs       Date:  2010-09       Impact factor: 2.248

4.  MDA-7/IL-24 inhibits cell survival by inducing apoptosis in nasopharyngeal carcinoma.

Authors:  Cheng Lin; Haibin Liu; Li Li; Qiubei Zhu; Huanhai Liu; Zhenghua Ji; Jianchun Liao; Juntian Lang; Jian Wu; Jingping Fan
Journal:  Int J Clin Exp Med       Date:  2014-11-15

5.  mda-7/IL-24 Induces Cell Death in Neuroblastoma through a Novel Mechanism Involving AIF and ATM.

Authors:  Praveen Bhoopathi; Nathaniel Lee; Anjan K Pradhan; Xue-Ning Shen; Swadesh K Das; Devanand Sarkar; Luni Emdad; Paul B Fisher
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

Review 6.  Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic.

Authors:  Rupesh Dash; Belal Azab; Xue-Ning Shen; Upneet K Sokhi; Siddik Sarkar; Zhao-zhong Su; Xiang-Yang Wang; Pier Paolo Claudio; Paul Dent; Igor P Dmitriev; David T Curiel; Steven Grant; Devanand Sarkar; Paul B Fisher
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

7.  Arsenic in leukemia: a RSKy business.

Authors:  Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-08-15       Impact factor: 4.742

Review 8.  Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer.

Authors:  Luni Emdad; Swadesh K Das; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2018-02-27       Impact factor: 6.384

9.  Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).

Authors:  Belal M Azab; Rupesh Dash; Swadesh K Das; Sujit K Bhutia; Siddik Sarkar; Xue-Ning Shen; Bridget A Quinn; Paul Dent; Igor P Dmitriev; Xiang-Yang Wang; David T Curiel; Maurizio Pellecchia; John C Reed; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2014-01       Impact factor: 6.384

Review 10.  Gene Therapies for Cancer: Strategies, Challenges and Successes.

Authors:  Swadesh K Das; Mitchell E Menezes; Shilpa Bhatia; Xiang-Yang Wang; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.